Related Experiment Videos
Human liver-derived HEP G2 cells produce functional properdin
1Department of Internal Medicine, Iowa City Veterans Affairs Medical Center, IA.
The Journal of Laboratory and Clinical Medicine
|December 1, 1994
Summary
This study demonstrates that Hep G2 cells produce functional properdin, a key complement pathway protein. This finding suggests hepatocytes may synthesize properdin, independent of interleukin-6 stimulation.
Area of Science:
- Immunology
- Molecular Biology
- Hepatology
Background:
- Properdin stabilizes the alternative complement pathway C3 convertase.
- Monocytes and myelomonocytic cell lines are known producers of properdin.
- Hepatic production of properdin has not been previously documented, despite the liver synthesizing most complement components.
Purpose of the Study:
- To investigate the potential of human liver-derived Hep G2 cells to produce properdin.
- To determine if interleukin-6 (IL-6) influences properdin production in Hep G2 cells.
- To confirm the functional activity of properdin produced by Hep G2 cells.
Main Methods:
- Polymerase chain reaction (PCR) to detect properdin messenger RNA (mRNA) in Hep G2 cells.
- Southern transfer and hybridization with a murine properdin cDNA probe for message confirmation.
- Sequencing of the PCR product to compare with known properdin sequences.
- Dot blot assays to quantify properdin in cell culture supernatants.
- Alternative pathway decay assays to assess properdin functional activity.
Main Results:
- Properdin mRNA was detected in Hep G2 cells, with sequences nearly identical to U937 cell properdin.
- Functional properdin was present in the culture supernatants of Hep G2 cells.
- Interleukin-6 (IL-6) stimulation did not significantly alter properdin production by Hep G2 cells.
- Properdin production was not found to be an acute phase reaction.
Conclusions:
- Human liver-derived Hep G2 cells synthesize functional properdin.
- Hepatocytes are a potential site for properdin biosynthesis.
- Properdin synthesis in Hep G2 cells is not modulated by IL-6, aligning with its non-acute phase reactant status.